Study of AZD2373 for APOL1-related kidney disease
Part of Genetic & congenital, Kidney & urinary clinical trials.
This trial tests an experimental drug (AZD2373) for people with kidney disease caused by APOL1 gene changes. It aims to find the safest and most effective dose to slow kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old and of African descent (for example, Black, African American, or Afro-Caribbean).
- You have a high-risk APOL1 gene type (G1/G1, G1/G2, or G2/G2).
- Your urine protein level (UACR) is 300 mg/g or higher, and your kidney function (eGFR) is at least 25.
- You do not have type 1 diabetes. If you have type 2 diabetes, your blood sugar control must be stable (A1c about 8% or less).
- You are not on dialysis or have had a kidney transplant, and you have no other major kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks if a new genetic test for the APOL1 gene works correctly. It uses samples from people who have already joined another drug trial.
This trial tests an experimental drug called MZE829 for people with kidney disease linked to the APOL1 gene. It aims to see if the drug can help protect kidney function.
This trial studies whether VX-147 can improve kidney disease caused by an APOL1 gene change, which often leads to protein leaking into the urine. It includes both adults and children and focuses on safety and effectiveness over time.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This trial tests a new drug called AZD7760 in two groups: healthy adults (Phase I) and adults with end-stage kidney disease who are on hemodialysis through a central venous catheter (Phase IIa). The goal is to see how safe the drug is and how the body processes it. This could lead to a new treatment option for people on dialysis.
This trial tests a new drug, ABBV-CLS-628, for people with autosomal dominant polycystic kidney disease (ADPKD). The goal is to see if it slows kidney function decline and is safe to use.
Hear when a new APOL1-Mediated Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.